Hydroflumethiazide composition for treating TNF-α-related diseases

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.

View original document View source feed page

What changed

USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a pharmaceutical composition comprising hydroflumethiazide as an active ingredient effective against TNF-α-related diseases. The composition was found to demonstrate superior treatment effects compared to existing rheumatoid arthritis drugs methotrexate and hydroxychloroquine. The patent covers compositions for treating inflammatory and autoimmune conditions including rheumatoid arthritis.

For pharmaceutical manufacturers and biotech companies, this patent represents a potential barrier to developing generic hydroflumethiazide formulations for TNF-α-related disease applications. Companies should conduct freedom-to-operate analyses before entering this therapeutic space. The patent may also present licensing opportunities for parties interested in developing this composition for TNF-α-mediated conditions.

What to do next

Review patent for freedom-to-operate analysis
Monitor patent family for related applications
Assess potential licensing opportunities

Source document (simplified)

← USPTO Patent Grants

Composition for preventing or treating TNF-α-related disease, comprising hydroflumethiazide as active ingredient

Grant US12594279B2 Kind: B2 Apr 07, 2026

Assignee

SK CHEMICALS CO., LTD.

Inventors

Soo Min Lee, Jong-In Kim, Nam-Jin Gu, Jeong-Hoon Kim, Dae Hee Han, Hee Jung Koo

Abstract

A composition for preventing or treating a TNF-α-related disease is disclosed. The composition includes hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient. The composition can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease.

CPC Classifications

A61K 31/549 A61K 31/5415 A61P 19/02 A61P 29/00 A61P 19/00 A61P 37/00 A61P 11/00 A61P 3/10 A23L 33/10 A23V 2200/314 A23V 2200/324 A23V 2200/328 A23V 2002/00